Man Group plc Acquires Shares of 24,443 AtriCure, Inc. $ATRC

Man Group plc bought a new position in AtriCure, Inc. (NASDAQ:ATRC) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 24,443 shares of the medical device company’s stock, valued at approximately $684,000.

Other institutional investors also recently bought and sold shares of the company. Geneos Wealth Management Inc. purchased a new position in AtriCure during the second quarter worth $37,000. Harbor Investment Advisory LLC bought a new stake in shares of AtriCure in the 2nd quarter worth about $40,000. Allworth Financial LP purchased a new position in shares of AtriCure during the 2nd quarter worth about $43,000. Smartleaf Asset Management LLC boosted its stake in shares of AtriCure by 59.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares during the period. Finally, Fifth Third Bancorp bought a new position in AtriCure during the 1st quarter valued at about $51,000. 99.11% of the stock is currently owned by institutional investors.

AtriCure Stock Down 0.2%

Shares of NASDAQ:ATRC opened at $52.46 on Friday. The business’s 50 day moving average is $39.67 and its 200 day moving average is $32.70. The stock has a market cap of $2.67 billion, a P/E ratio of 249.82 and a beta of 1.26. AtriCure, Inc. has a 52-week low of $25.36 and a 52-week high of $53.50. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The business had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. During the same period in the previous year, the company posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Sell-side analysts predict that AtriCure, Inc. will post 0.29 EPS for the current year.

Insider Transactions at AtriCure

In related news, Director Sven Wehrwein sold 25,000 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total value of $946,000.00. Following the completion of the sale, the director directly owned 40,518 shares of the company’s stock, valued at $1,533,201.12. This represents a 38.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Maggie Yuen sold 3,500 shares of the stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total transaction of $134,470.00. Following the transaction, the director owned 14,015 shares in the company, valued at approximately $538,456.30. The trade was a 19.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 53,616 shares of company stock valued at $2,149,994 over the last three months. 4.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Zacks Research cut AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. Raymond James Financial set a $52.00 price target on AtriCure in a report on Tuesday, July 21st. BTIG Research upped their price objective on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, August 24th. Finally, Needham & Company LLC increased their target price on AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $52.00.

AtriCure Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.